When to Switch a Drug Class in Psoriasis Treatment

Dermatologists discuss their approach to managing patients who have experienced treatment failure. They debate whether to switch to a different class of drug or remain within the same class based on factors such as primary versus secondary failure and individual patient response. They also mention specific drugs within the class, like bimekizumab, and discuss the efficacy and considerations of different options. The conversation highlights the complexity of decision-making in dermatology regarding treatment selection for patients who have not responded to TNF blockers.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.